# Study of Lacutamab in Peripheral T-cell Lymphoma

> **NCT04984837** · PHASE2 · RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 56 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma
- Relapse/Recurrence

## Interventions

- **DRUG:** Lacutamab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatine

## Key facts

- **NCT ID:** NCT04984837
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-05
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984837, "Study of Lacutamab in Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04984837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*